Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
James T PetersonHelen L StaceyJohn E MacNairJianing LiJonathan S HartzelTina M SterlingPatrice BennerGretchen M TammsLuwy K MuseyPublished in: Human vaccines & immunotherapeutics (2018)
PCV15 was generally well tolerated and induced high levels of IgG and OPA antibodies to all 15 serotypes included in the vaccine when given as a single dose to adults ≥ 65 years of age previously vaccinated with PPV23.